Gabapentin Dementia Lawsuit in Alabama

Time limits apply in Alabama. Find out if you still qualify.

Free Case Review

Check your eligibility — free

Answer 2-3 quick questions to review your potential case.

Key takeaway

Alabama ranks among the highest gabapentin-prescribing states in the nation, with per-capita prescription rates nearly double the national average — a pattern driven by elevated chronic pain prevalence, limited specialist access in rural counties, and the state's severe opioid crisis that pushed physicians toward gabapentinoids as alternatives. Alabama classified gabapentin as a Schedule V controlled substance in 2019, acknowledging the misuse and dependence potential that manufacturers had long minimized. The state's prescription drug monitoring program data reveals gabapentin is frequently co-prescribed with opioids in Alabama, a combination the FDA warned in 2019 can cause respiratory depression and death. Jefferson County (Birmingham) and Mobile County courts have active pharmaceutical litigation dockets, and Alabama's plaintiff-friendly venue rules make it a strong jurisdiction for gabapentin cognitive decline claims.

People's Justice Research TeamUpdated June 11, 2026Fact-checked

Verified against court and regulatory records · No upfront fees · Your information is never sold

Statute of limitations — Alabama

Alabama: 2 years for product liability (Ala. Code § 6-2-38(l)). Discovery rule applies — the limitations period begins when the plaintiff discovers or reasonably should have discovered the injury and its connection to gabapentin. Alabama also has a 10-year statute of repose for product liability claims (Ala. Code § 6-5-502).

2 years from discovery of injury

Filing venue

Where to File in Alabama

Gabapentin dementia cases in Alabama may be filed in federal court in the Northern District (Birmingham), Middle District (Montgomery), or Southern District (Mobile). Jefferson County Circuit Court in Birmingham is a historically plaintiff-favorable venue for pharmaceutical litigation. Alabama classified gabapentin as a Schedule V controlled substance, and PDMP data can support claims about prescribing patterns. Alabama applies the Alabama Extended Manufacturer's Liability Doctrine (AEMLD) for product liability claims.

Alabama data

Exposure in Alabama

Alabama's annual gabapentin prescribing volume of approximately 1.8 million prescriptions for a population of 5.1 million represents one of the highest per-capita rates nationally. Rural counties in north Alabama and the Black Belt region show the most concentrated prescribing, driven by chronic pain from agricultural and manufacturing occupations and limited access to multimodal pain management.

~1.8M gabapentin Rx/year in AL

Source: IQVIA / CDC prescribing data

Alabama classified gabapentin as a Schedule V controlled substance effective January 2019, requiring prescriptions to be reported to the state's Prescription Drug Monitoring Program (PDMP). This regulatory action acknowledged gabapentin's misuse potential and physical dependence risk — facts the manufacturer had long downplayed in product labeling.

Schedule V since 2019

Source: Alabama Board of Pharmacy

Nearly half of Alabama gabapentin prescriptions are written concurrently with opioid medications, creating dangerous polypharmacy combinations that amplify both respiratory depression and cognitive impairment risks. Alabama's opioid prescribing rate of 84 prescriptions per 100 persons in 2020 was among the highest in the nation, creating a massive overlap population.

47% opioid co-prescribing rate

Source: CDC Opioid Prescribing Data / AL PDMP

FAQ

Frequently Asked Questions

12 QUESTIONS

The evidence is now stronger than at any point in gabapentin's 30-year history. A July 2025 study published in Regional Anesthesia & Pain Medicine — one of the largest population-level analyses ever conducted on gabapentin's cognitive effects — found that patients who filled six or more gabapentin prescriptions had a 29% increased risk of developing dementia compared to matched controls. For patients aged 35 to 49, dementia risk doubled. The study also found an 85% increased risk of mild cognitive impairment, which is widely recognized as a precursor to dementia. Gabapentin works by binding to calcium channels in the brain that are essential for memory formation and learning. When those channels are chronically suppressed by daily gabapentin use, the result appears to be a gradual degradation of cognitive function that, in some patients, progresses to clinical dementia.

Gabapentin-related cognitive decline often begins subtly and is frequently attributed to stress, aging, or the underlying condition being treated. Early warning signs include increased forgetfulness — missing appointments, repeating questions, losing track of conversations. You or your family may notice difficulty with tasks that require planning or sequencing, like managing bills, following recipes, or navigating familiar routes. Word-finding problems — pausing mid-sentence to search for a common word — are another hallmark. Slower processing speed (taking longer to understand instructions or respond in conversation) and mental fog that doesn't clear with rest are also characteristic. The critical distinction from normal aging is the pace and severity of decline. If these symptoms developed or accelerated after starting gabapentin or after a dosage increase, the temporal relationship is significant and should be discussed with your doctor and documented for legal purposes.

First, you must have taken gabapentin (Neurontin or generic) chronically — generally six or more prescription fills or continuous use for a year or longer. Second, you must have developed documented cognitive symptoms: memory loss, confusion, difficulty concentrating, impaired executive function, or a formal diagnosis of mild cognitive impairment or dementia. Third, your cognitive decline must have occurred during or after your gabapentin use — temporal correlation is essential. Fourth, you should not have had a pre-existing neurodegenerative diagnosis (like Alzheimer's or Lewy body disease) before starting gabapentin. Pharmacy records documenting your gabapentin prescription history and medical records documenting your cognitive symptoms are the two most important pieces of evidence. A free case evaluation with a pharmaceutical injury attorney can help determine whether your specific circumstances support a claim.

The July 2025 study identified a clear dose-response relationship: the risk threshold was six or more gabapentin prescription fills. For a typical 30-day prescription, that translates to approximately six months of use — though many patients take gabapentin continuously for years. The study found that risk increased with cumulative exposure, meaning longer use correlated with higher dementia and MCI risk. Importantly, the study also showed that even within the six-prescription threshold group, younger patients (ages 35-49) faced dramatically elevated risk — suggesting that individual susceptibility varies and that no duration of chronic use should be considered categorically safe. Patients who took gabapentin at higher doses (1,800mg/day or above) for shorter periods may face comparable risk to those on lower doses for longer periods, as total cumulative brain exposure is the key variable.

As of early 2026, there is no certified class action for gabapentin-related cognitive decline. The litigation is in its emerging phase, with individual lawsuits being filed across multiple jurisdictions. Pharmaceutical injury attorneys are investigating claims and building the scientific and legal framework for what may become coordinated litigation — potentially through multi-district litigation (MDL) consolidation if sufficient cases are filed in federal court. Historically, major pharmaceutical injury litigations (Vioxx, Zantac, Roundup) began with individual filings before evolving into coordinated proceedings. The July 2025 study provides the foundational general causation evidence that is typically required before litigation achieves critical mass. Patients should not wait for a class action to be certified before consulting an attorney — statutes of limitations are running, and early filers often have the strongest cases.

Do not stop taking gabapentin abruptly. Sudden discontinuation of gabapentin can cause serious withdrawal symptoms including seizures — even in patients who were not taking the drug for epilepsy. Gabapentin must be tapered gradually under medical supervision, typically reducing the dose by no more than 25% per week. If you are concerned about cognitive effects, schedule an appointment with your prescribing physician to discuss your concerns, the July 2025 study findings, and a supervised tapering plan. Ask your doctor about alternative treatments for your underlying condition that have lower cognitive risk profiles. Simultaneously, request a formal cognitive assessment (neuropsychological evaluation) to establish a documented baseline of your current cognitive function — this serves both your medical care and your potential legal claim.

Statutes of limitations for pharmaceutical injury claims vary by state, typically ranging from one to six years. However, the critical question for gabapentin cases is when the clock starts running. Most states apply a 'discovery rule' — the limitations period begins when the patient knew or reasonably should have known that gabapentin caused their cognitive decline. For many patients, the July 2025 study represents the first time the gabapentin-dementia connection became publicly known, which may serve as the triggering discovery event. Tennessee has the shortest major-state SOL at one year, while states like Florida allow up to four years for product liability. Regardless of your state, the safest course is to consult an attorney as soon as possible — every month of delay increases the risk that a court will find you should have discovered the connection sooner.

Because this litigation is emerging, no specific gabapentin cognitive decline verdicts or settlements have been publicly reported. However, projections based on comparable pharmaceutical injury litigation suggest a wide range depending on the severity of cognitive impairment. Cases involving mild cognitive impairment with preserved daily function may fall in the $50,000 to $150,000 range. Early-onset dementia requiring some caregiver assistance could value between $200,000 and $500,000. Advanced dementia with total loss of independence may reach $400,000 to over $1 million. Wrongful death claims where gabapentin-associated cognitive decline contributed to death could exceed $2 million. Individual case value depends on age at diagnosis, documented gabapentin exposure history, severity of cognitive impairment, economic losses (lost income, care costs), and the strength of the causal connection established by medical experts.

Building a strong gabapentin cognitive decline claim requires two categories of evidence. First, you need complete documentation of your gabapentin exposure: pharmacy dispensing records showing every gabapentin prescription filled (date, dosage, quantity, refills), medical records showing the diagnosis for which gabapentin was prescribed, and any records of dosage changes or duration of continuous use. Most pharmacies maintain electronic records going back 10 or more years, and your insurance company or pharmacy benefit manager can provide claims history. Second, you need documentation of your cognitive decline: neuropsychological evaluation results, brain imaging (MRI), any formal diagnosis of MCI or dementia, and records from family members or employers documenting functional changes. The temporal relationship between gabapentin use and cognitive symptom onset is one of the strongest pieces of evidence your attorney can present.

The 2004 $430 million DOJ settlement resolved criminal charges related to Warner-Lambert's illegal off-label promotion of Neurontin — it did not resolve individual personal injury claims from patients harmed by the drug. The 2004 settlement is directly relevant to current litigation because it established, through Pfizer's own guilty plea, that gabapentin was systematically promoted for uses the FDA never approved and for which safety data was inadequate. If you were prescribed gabapentin for an off-label condition (pain, anxiety, insomnia, migraines, or other non-epilepsy, non-postherpetic neuralgia uses), the 2004 settlement strengthens the argument that you were exposed to gabapentin as a direct result of the company's illegal marketing practices. Your individual cognitive decline claim is separate from and not barred by the 2004 settlement.

Yes — the cognitive decline risk identified in the July 2025 study applies to gabapentin regardless of whether it was dispensed as brand-name Neurontin or a generic equivalent. Generic gabapentin contains the same active ingredient at the same dose and must meet the same FDA bioequivalence standards as the branded product. The neurotoxicity mechanism — chronic binding to alpha-2-delta calcium channel subunits in the brain — is a property of the gabapentin molecule itself, not of any particular manufacturer's formulation. The overwhelming majority of gabapentin prescriptions filled today are generic, as Neurontin's patent expired in 2004. For legal purposes, claims can be brought against both the original brand manufacturer (Pfizer) for failure to warn and inadequate labeling, and potentially against generic manufacturers under state consumer protection theories, depending on jurisdiction.

This was perhaps the most alarming finding of the July 2025 study. Adults aged 35 to 49 who used gabapentin chronically experienced a doubling of dementia risk and a tripling of MCI risk — the highest relative risk elevation of any age group studied. This is extraordinary because early-onset dementia in this age range is otherwise quite rare. The finding suggests that gabapentin may be triggering neurodegenerative processes in patients whose brains should be decades away from cognitive decline. Younger patients are often prescribed gabapentin for chronic pain conditions, fibromyalgia, anxiety, or migraines — all off-label uses that Pfizer's subsidiary was convicted of illegally promoting. If you are under 50 and experiencing memory problems, confusion, or cognitive difficulties while taking or after taking gabapentin, the July 2025 research suggests your age does not protect you — in fact, the data suggests younger chronic users face the steepest relative risk increase.

Keep reading

← Back to Gabapentin Dementia Lawsuit Lawsuit Overview Track the Gabapentin Dementia Lawsuit litigation timeline →

Quick Eligibility Review

Check your eligibility — free

Where to File in Alabama

Exposure in Alabama

Frequently Asked Questions

Can gabapentin cause dementia?

What are the signs of gabapentin-related cognitive decline?

Who qualifies for a gabapentin dementia lawsuit?

How long does gabapentin need to be taken before dementia risk increases?

Is there a gabapentin class action lawsuit?

Should I stop taking gabapentin if I'm worried about dementia?

What is the statute of limitations for gabapentin dementia claims?

How much are gabapentin dementia cases worth?

What evidence do I need for a gabapentin cognitive decline claim?

Does the 2004 Pfizer settlement affect my gabapentin dementia case?

Is generic gabapentin as risky as brand-name Neurontin?

Can younger adults develop early-onset dementia from gabapentin?